BROSSARD, Quebec, March 27, 2019 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:
ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its proprietary
FLAIRE platform based on Artificial Intelligence (AI), announces today the
signing of a memorandum of understanding to establish a framework between one hospital in the US and DIAGNOS.
Under the terms of a mutual non-disclosure agreement, the name of the hospital can’t be disclosed. The
hospital is engaged and specializes in the medical field of stroke and related cardiological issues. The hospital has one of
the largest databases in the world for stroke related patients. DIAGNOS will utilize this database to finalize the development and
validation for CARDIO.
CARDIO is an application that predicts the future risk of a patient having a stroke or other conditions that may
lead to a stroke. ‘’We are honored to form this relationship with a hospital and team of clinicians that are truly experts in
the field of stroke. Using our FLAIRE platform we are able to analyse the retina and derive the key
features that predict a stroke. Having access to the thousands of medical records from our hospital partner will enable
DIAGNOS to finish the development and testing of the application. The screening will be done with the same commercial fundus
camera used for identifying retinopathy with diabetic patients’’, said Dr. Reid Maclellan, director at DIAGNOS.
The Corporation is also announcing that a new date of April 10th, 2019 has been fixed for the meeting
of the Debentureholders initially scheduled for April 4th, 2019 as stated in the Corporate Reorganization press release
of March 11th, 2019. The decision of rescheduling the meeting date to April 10th, 2019 was undertaken to
allow the Corporation to efficiently comply with the mailing of meeting material requirements.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of
its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that
integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image
enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the
internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a
cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for
commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking
compliant in Europe.
Additional information is available at www.diagnos.com and www.sedar.com
For further information, please contact:
This news release contains forward-looking information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.